Oral drug developer Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP.OB))will present a study at a conference in Rome.
The abstract - “Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Five Oral Insulin Formulations in Healthy Subjects,” - has been chosen for presentation at the upcoming 44th annual meeting of the European association for the study of diabetes (EASD) in Rome. The report will be shown as a poster presentation, and highlights the successful results from its oral insulin trials on healthy volunteers.
Though the poster will be viewable throughout the conference, Oramed chief scientific officer Dr. Miriam Kidron and Oramed director of research and development Dr. Ehud Arbit will present the poster on Tuesday, Sept. 9, from 12:30 p.m. to 1:30 p.m.
“The fact that Oramed has been selected to present research at the EASD Conference underscores the importance of our work developing an oral insulin capsule,” said Oramed CEO Nadav Kidron. “We look forward to sharing the results of our Phase 1B trials with top diabetes researchers from around the world.”
The European association for the study of diabetes is comprised of a global membership of scientists, doctors, laboratory workers, nurses, and students who are interested in diabetes and related subjects. Active members hold a medical degree or are scientific workers with an academic degree. It holds a meeting each year in a different city in Europe.
Published by Globes [online], Israel business news - www.globes-online.com - on August 24, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008